Ethoxy acetalated dextran-based nanocarriers accomplish efficient inhibition of leukotriene formation by a novel FLAP antagonist in human leukocytes and blood

in: Cellular and Molecular Life Sciences (2022)
Kretzer, Christian; Shkodra-Pula, Blerina; Klemm, Paul; Jordan, Paul M.; Schröder, Daniel; Cinar, Gizem; Vollrath, Antje; Schubert, Stephanie; Nischang, Ivo; Hoeppener, Stephanie; Stumpf, Steffi; Banoglu, Erden; Gladigau, Frederike; Bilancia, Rossella; Rossi, Antonietta; Eggeling, Christian; Neugebauer, Ute; Schubert, Ulrich S.; Werz, Oliver
Leukotrienes are pro-infammatory lipid mediators generated by 5-lipoxygenase aided by the 5-lipoxygenase-activating protein (FLAP). BRP-201, a novel benzimidazole-based FLAP antagonist, inhibits leukotriene biosynthesis in isolated leukocytes. However, like other FLAP antagonists, BRP-201 fails to efectively suppress leukotriene formation in blood, which limits its therapeutic value. Here, we describe the encapsulation of BRP-201 into poly(lactide-co-glycolide) (PLGA) and ethoxy acetalated dextran (Ace-DEX) nanoparticles (NPs), aiming to overcome these detrimental pharmacokinetic limitations and to enhance the bioactivity of BRP-201. NPs loaded with BRP-201 were produced via nanoprecipitation and the physicochemical properties of the NPs were analyzed in-depth using dynamic light scattering (size, dispersity, degradation), electrophoretic light scattering (efective charge), NP tracking analysis (size, dispersity), scanning electron microscopy (size and morphology), UV–VIS spectroscopy (drug loading), an analytical ultracentrifuge (drug release, degradation kinetics), and Raman spectroscopy (chemical attributes). Biological assays were performed to study cytotoxicity, cellular uptake, and efciency of BRP-201-loaded NPs versus free BRP-201 to suppress leukotriene formation in primary human leukocytes and whole blood. Both PLGA- and Ace-DEX-based NPs were signifcantly more efcient to inhibit leukotriene formation in neutrophils versus free drug. Whole blood experiments revealed that encapsulation of BRP-201 into Ace-DEX NPs strongly increases its potency, especially upon pro-longed (≥5 h) incubations and upon lipopolysaccharide-challenge of blood. Finally, intravenous injection of BRP-201-loaded NPs signifcantly suppressed leukotriene levels in blood of mice in vivo. These results reveal the feasibility of our pharmacological approach using a novel FLAP antagonist encapsulated into Ace-DEX-based NPs with improved efciency in blood to suppress leukotriene biosynthesis.

Cookies & Skripte von Drittanbietern

Diese Website verwendet Cookies. Für eine optimale Performance, eine reibungslose Verwendung sozialer Medien und aus Werbezwecken empfiehlt es sich, der Verwendung von Cookies & Skripten durch Drittanbieter zuzustimmen. Dafür werden möglicherweise Informationen zu Ihrer Verwendung der Website von Drittanbietern für soziale Medien, Werbung und Analysen weitergegeben.
Weitere Informationen finden Sie unter Datenschutz und im Impressum.
Welchen Cookies & Skripten und der damit verbundenen Verarbeitung Ihrer persönlichen Daten stimmen Sie zu?

Sie können Ihre Einstellungen jederzeit unter Datenschutz ändern.